On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。